Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Sudarshan Sukhani of s2analytics.com recommends buying pharma stocks.
Dipan Mehta, Member at BSE & NSE is of the view that one may prefer largecap pharma names over midcap pharma names.
Kunal Saraogi, CEO at Equityrush is of the view that one may hold Cipla.
Watch the interview of Kunal Saraogi, CEO of Equityrush who shared his readings and outlook on specific stocks and sector & Hemant Rustagi, CEO of Wiseinvest Advisors answered few personal finance queries.
Anmol Ganjoo of JM Financial Institutional Securities is of the view that one may prefer Dr Reddy's Laboratories, Lupin, Cipla, Ipca Labs and Torrent Pharma.
Sudarshan Sukhani of s2analytics.com is of the view that one may look at Cipla.
According to CK Narayan, MD at Growth Avenues, one can buy Hindustan Unilever, Dabur India, Cipla and Glenmark Pharma.
Devang Mehta of Anand Rathi Financial Services is of the view that one may look at pharma, IT and FMCG space.
Here are top 10 stocks to keep an eye on March 9 - TCS, CIPLA, Unitech, JSPL, Hindalco, Ambuja Cement, Monet Ispat L&T, Pipavav Defence and Mindtree. Our research team is also tracking - Repco Home Finance, Dewan Housing, Gruh Finance and Power Grid and Concor.
Sudarshan Sukhani of s2analytics.com is of the view that one may look at Cipla and Axis Bank.
Sameet Chavan of Angel Broking recommends buying Cipla with a target of Rs 740 and is optimistic on Tata Communications and feels that the stock may test Rs 430.
Sudarshan Sukhani of s2analytics.com recommends buying Cipla.
Amit Trivedi of Investworks.in is of the view that one may buy Cipla 700 Call and sell 720 Call.
Rajat Bose of rajatkbose.com recommends buying Cipla and ITC.
Manoj Murlidharan of Religare Securities recommmends buying Colgate Palmolive, Cipla and Coal India buy advises selling HDFC and Axis Bank.
Here are top 10 stocks to keep an eye on February 6 - Unitech, GMR Infra, Tata Motors, UCO Bank, PTC India Limited, Ceat,Hindustan Copper Ltd, Jubilant Foodworks, Sarda Energy, Godfrey Phillips, Mercator, AIA Engineering, Ramco Industries Ltd, Bharti Airtel & Cipla.
Sudarshan Sukhani of s2analytics.com advises to prefer Cipla.
Deven Choksey of KR Choksey Shares & Securities recommends accumulating Dr Reddy's Laboratories on every dip and feels that Glenmark Pharma and Cipla holds good potential for an upmove going forward.
The US FDA‘s decision to revoke the 180-day exclusivity cover extended to Indian firm Ranbaxy to sell a generic version of the world‘s second-largest selling drug esomeprazole is likely to help rival Cipla, according to Vivek Kumar, research analyst, SBICap Securities.
Pritesh Mehta of IIFL is of the view that one may prefer Cipla, Sun Pharma and Lupin.
Nooresh Merani, CEO at Analyse India advises buying Cipla on dips.
Here are top 10 stocks to focus on January 13 - Cairn India, Jet Airways, Apollo Tyres, Ceat, Crompton Greaves, Bank Nifty, Hindalco, CMC, Clariant Chemicals and Spicejet. We are also watching Dr Reddy's, Sun Pharma, Ipca Labs, Lupin, Cipla, ACC and Ultratech.
According to Sudarshan Sukhani of s2analytics.com, one may buy Cipla.
Amit Trivedi of Investworks.in suggests buying Cipla 620 call and selling 640 and 660 calls.
Here are top 10 stocks to focus on January 6 – Cairn India, ONGC, HPCL, Andhra Bank, Idea Cellular, Bharti Airtel, Sesa Sterlite, Cipla, IRB Infra and Syndicate Bank.